Latest Global Markets News

Admiralty Resources has secured a pivotal contract with global trader Trafigura to market its Mariposa Iron Ore, marking a key step towards commercial production and revenue generation.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Airtasker Limited showcased strong FY25 financials and unveiled aggressive growth plans in the UK and US, supported by strategic media partnerships and core platform investments.

Element 25 Limited has announced significant progress in expanding its Butcherbird manganese mine and developing a US-based high-purity manganese refinery, backed by substantial government grants and strategic partnerships with automotive giants.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Synertec has secured a pivotal contract to supply its zero-emission Powerhouse system to Shell QGC’s Coal Seam Gas operations in Queensland, marking a significant step in industrial decarbonisation.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

PC Gold has secured a dual listing on the Frankfurt Stock Exchange, opening new doors to European investors as it advances its Spring Hill Gold Project in Australia’s Northern Territory.

Atturra Limited reported a robust 24% increase in both revenue and underlying EBITDA for FY25, propelled by its cloud platform, AI innovations, and defence sector contracts. The company forecasts continued momentum into FY26 with ambitious growth targets.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.